Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Thoracic Malignancies
What ipsilateral lung constraints if any do you utilize for SBRT and or hypofractionated RT in the lungs?
Do you consider mean ipsilateral lung dose?
Related Questions
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
What is the role for molecular agents alone for medically inoperable NSCLC who is not a good candidate for chemoRT?
Would you recommend post op radiation therapy for a primary pulmonary synovial sarcoma which underwent lobectomy?
How would you manage out-of-field nodal recurrence of NSCLC post definitive CRT and adjuvant immunotherapy?
How do you manage a cytology-negative pleural effusion that develops after lung RT?
How would you manage persistent chest wall disease after adjuvant chemoRT s/p lobectomy for T3N0 NSCLC with an involved margin?
How do you instruct patients taking sucralfate?
How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
How would you delineate or modify target volumes for stage I NSCLC abutting the chest wall in a thin patient for whom the traditional SBRT PTV margin extends to the skin?